Harel Insurance Investments & Financial Services Ltd. Buys New Position in Moderna, Inc. (NASDAQ:MRNA)

Harel Insurance Investments & Financial Services Ltd. bought a new stake in Moderna, Inc. (NASDAQ:MRNA) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 15,000 shares of the company’s stock, valued at approximately $624,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp lifted its position in shares of Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Moderna by 2.6% during the third quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after buying an additional 178,115 shares during the period. Wellington Management Group LLP boosted its holdings in Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after purchasing an additional 906,114 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Moderna by 0.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock valued at $260,023,000 after acquiring an additional 19,819 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in Moderna by 6.2% during the third quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock valued at $205,431,000 after purchasing an additional 178,939 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Price Performance

MRNA stock opened at $41.41 on Friday. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The firm has a 50 day moving average of $40.60 and a 200 day moving average of $64.04. Moderna, Inc. has a 52 week low of $31.94 and a 52 week high of $170.47.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The company had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same period last year, the firm earned ($1.39) EPS. The firm’s revenue for the quarter was up 3.8% compared to the same quarter last year. Equities analysts predict that Moderna, Inc. will post -9.27 EPS for the current fiscal year.

Insider Activity at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. This represents a 6.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders have sold 2,664 shares of company stock worth $115,210. 15.70% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Argus cut shares of Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Sanford C. Bernstein initiated coverage on shares of Moderna in a research report on Thursday, October 17th. They set a “market perform” rating and a $55.00 price target on the stock. Hsbc Global Res upgraded shares of Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Barclays lowered their price objective on Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research note on Friday, November 8th. Finally, Berenberg Bank boosted their price objective on shares of Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a report on Thursday, January 16th. Four investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $75.58.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.